User menu

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.

Bibliographic reference Feltes, Timothy F ; Sondheimer, Henry M ; Tulloh, Robert M R ; Harris, Brian S ; Jensen, Kathryn M ; et. al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.. In: Pediatric research, Vol. 70, no.2, p. 186-91 (2011)
Permanent URL http://hdl.handle.net/2078/123894
  1. Shay David K., Bronchiolitis-Associated Hospitalizations Among US Children, 1980-1996, 10.1001/jama.282.15.1440
  2. Welliver Robert C, Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection, 10.1067/s0022-3476(03)00508-0
  3. Groothuis JR, Pediatrics, 82, 199 (1988)
  4. Hall Caroline Breese, Kopelman Arthur E., Douglas R. Gordon, Geiman Joyce M., Meagher Mary Pat, Neonatal Respiratory Syncytial Virus Infection, 10.1056/nejm197902223000803
  5. Heilman C. A., From the National Institute of Allergy and Infectious Diseases and the World Health Organization: Respiratory Syncytial and Parainfluenza Viruses, 10.1093/infdis/161.3.402
  6. MacDonald Noni E., Hall Caroline Breese, Suffin Stephen C., Alexson Chloe, Harris Peter J., Manning James A., Respiratory Syncytial Viral Infection in Infants with Congenital Heart Disease, 10.1056/nejm198208123070702
  7. Johnson Syd, Oliver Cynthia, Prince Gregory A., Hemming Val G., Pfarr David S., Wang Sheau‐Chiann, Dormitzer Melissa, O'Grady John, Koenig Scott, Tamura James K., Woods Robert, Bansal Geetha, Couchenour Debra, Tsao Eric, Hall William C., Young James F., Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus, 10.1086/514115
  8. , Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections, 10.1542/peds.2009-2345
  9. , Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants, 10.1542/peds.102.3.531
  10. Feltes Timothy F, Cabalka Allison K, Meissner H.Cody, Piazza Franco M, Carlin David A, Top Franklin H, Connor Edward M, Sondheimer Henry M, for the Cardiac Synagis Study Group, Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease, 10.1067/s0022-3476(03)00454-2
  11. Mejias A., Chavez-Bueno S., Rios A. M., Aten M. F., Raynor B., Peromingo E., Soni P., Olsen K. D., Kiener P. A., Gomez A. M., Jafri H. S., Ramilo O., Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency, 10.1128/aac.49.11.4700-4707.2005
  12. Wu Herren, Pfarr David S., Tang Ying, An Ling-Ling, Patel Nita K., Watkins Jeffry D., Huse William D., Kiener Peter A., Young James F., Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization, 10.1016/j.jmb.2005.04.049
  13. Wu Herren, Pfarr David S., Johnson Syd, Brewah Yambasu A., Woods Robert M., Patel Nita K., White Wendy I., Young James F., Kiener Peter A., Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract, 10.1016/j.jmb.2007.02.024
  14. Abarca Katia, Jung Elizabeth, Fernández Pilar, Zhao Liang, Harris Brian, Connor Edward M., Losonsky Genevieve A., Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children : , 10.1097/inf.0b013e31818ffd03
  15. Lagos Rosanna, DeVincenzo John P., Muñoz Alma, Hultquist Micki, Suzich JoAnn, Connor Edward M., Losonsky Genevieve A., SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)–SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN : , 10.1097/inf.0b013e3181a165e4
  16. Carbonell-Estrany X., Simoes E. A. F., Dagan R., Hall C. B., Harris B., Hultquist M., Connor E. M., Losonsky G. A., , Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial, 10.1542/peds.2008-1036
  17. Chan Ivan S. F., Zhang Zhongxin, Test-Based Exact Confidence Intervals for the Difference of Two Binomial Proportions, 10.1111/j.0006-341x.1999.01202.x
  18. GUESS HARRY A., LYDICK EVA G., SMALL ROBERT D., MILLER LINDA P., EXACT BINOMIAL CONFIDENCE INTERVALS FOR THE RELATIVE RISK IN FOLLOW-UP STUDIES WITH SPARSELY STRATIFIED INCIDENCE DENSITY DATA1, 10.1093/oxfordjournals.aje.a114535